IDXX

SEC source: 0001140361-16-089024 · doc1.xml · derivative · entry 3

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,157

Underlying: Common Stock · 962 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F2 · price: Not applicable.

F1 · derivative.exercise_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F1 · derivative.expiration_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

SEC source: 0001140361-16-089024 · doc1.xml · nonDerivative · entry 2

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,593

SEC source: 0001140361-16-089024 · doc1.xml · nonDerivative · entry 1

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-16-088676 · doc1.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,203

Underlying: Common Stock · 2,203 shares

Expires 2026-11-30

F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on October 19, 2016 until the 2017 annual meeting of stockholders.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 3, 2017.

SEC source: 0001140361-16-088676 · doc1.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207

Underlying: Common Stock · 207 shares

Expires not disclosed

F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on October 19, 2016 until the 2017 annual meeting of stockholders.

F2 · derivative.exercise_price: Each deferred stock unit ("DSU") represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2017 annual meeting of stockholders or May 3, 2017, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F4 · price: Not applicable.

F2 · derivative.exercise_date: Each deferred stock unit ("DSU") represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2017 annual meeting of stockholders or May 3, 2017, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit ("DSU") represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2017 annual meeting of stockholders or May 3, 2017, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001140361-16-088670 · doc1.xml · derivative · entry 2

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,480

Underlying: Common Stock · 800 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-16-088670 · doc1.xml · nonDerivative · entry 1

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 52 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016.

SEC source: 0001140361-16-088284 · doc1.xml · derivative · entry 9

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 14,236 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-16-088284 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 990,431

F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $119.82 to a high of $120.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-16-088284 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,004,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-16-088284 · doc1.xml · derivative · entry 8

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,576 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F4 · derivative.exercise_date: Grant of option to buy 1,288 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-16-088284 · doc1.xml · derivative · entry 7

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,236

Underlying: Common Stock · 13,188 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-16-088284 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 990,431

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-16-088284 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987,855

F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $119.40 to a high of $119.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-16-088284 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,001,043

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-16-087991 · doc1.xml · derivative · entry 3

CRAIG THOMAS · CIK 0001184156 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,924 shares

Expires 2017-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,962 shares on February 14, 2011, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-16-087991 · doc1.xml · nonDerivative · entry 2

CRAIG THOMAS · CIK 0001184156 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,283

F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $119.5082 to a high of $120.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-16-087991 · doc1.xml · nonDerivative · entry 1

CRAIG THOMAS · CIK 0001184156 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-16-087477 · doc1.xml · derivative · entry 2

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,306

Underlying: Common Stock · 2,204 shares

Expires 2019-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy 5,255 shares of IDEXX Laboratories, Inc. common stock that is exercisable in five annual installments of 1,051 shares each beginning on September 1, 2013, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-16-087477 · doc1.xml · nonDerivative · entry 1

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 63 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016.

SEC source: 0001140361-16-085872 · doc1.xml · derivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,250

Underlying: Common Stock · 40,000 shares

Expires 2017-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Not applicable.

F6 · derivative.exercise_date: Grant of option to buy 78,125 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 16,000 shares each beginning on February 14, 2011 and as to the remaining 14,125 shares on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-16-085872 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987,855

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $107.90 to a high of $108.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-16-085872 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,015,655

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $106.87 to a high of $107.835 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-16-085872 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,022,088

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $105.81 to a high of $106.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-16-085872 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,027,855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 65 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016.

SEC source: 0001140361-16-085650 · doc1.xml · nonDerivative · entry 1

END WILLIAM T · CIK 0001184157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,654

F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $109.60 to a high of $109.9975 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-16-084225 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,454

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($5,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-16-084224 · doc1.xml · nonDerivative · entry 1

CRAIG THOMAS · CIK 0001184156 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,859

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($17,500.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-17-010771 · doc1.xml · derivative · entry 3

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,924 shares

Expires 2017-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,962 shares on February 14, 2011, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-17-010771 · doc1.xml · nonDerivative · entry 2

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,450

F1 · balance_after: This Form 4 is being amended solely to correct the number of shares of common stock beneficially owned by the reporting person following the reported transactions on the date of the transactions.

SEC source: 0001140361-17-010771 · doc1.xml · nonDerivative · entry 1

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This Form 4 is being amended solely to correct the number of shares of common stock beneficially owned by the reporting person following the reported transactions on the date of the transactions.